Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen™ for Multiple Sclerosis Nov 21, 2014
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time Sep 22, 2014
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R) Aug 11, 2014
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R) Jun 11, 2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity May 12, 2014
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors May 5, 2014
